Research programme: JNK inhibitors - Eisai

Drug Profile

Research programme: JNK inhibitors - Eisai

Alternative Names: Compound A; Compound B; ER 181304

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eisai Co Ltd
  • Class Indoles
  • Mechanism of Action JNK mitogen-activated protein kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Multiple sclerosis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in United Kingdom (PO)
  • 13 Nov 2010 Pharmacodynamics data from preclinical studies in Multiple sclerosis presented at the 40th Annual Meeting of the Society for Neuroscience (SFN-2010) ,
  • 02 Nov 2006 Preclinical trials in Parkinson's disease in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top